Peretz Partensky
Directeur Général chez ImmuneBridge, Inc.
Profil
Peretz Partensky is the founder of Sourcery Technologies, Inc. (founded in 2012) and ImmuneBridge, Inc. (founded in 2018), where he holds the title of Chief Executive Officer.
He is currently working as an Associate at Lemnos Labs, Inc. and as a Venture Partner at Pioneer Fund.
Dr. Partensky received a graduate degree from the University of Cambridge in 2004 and a doctorate degree from the University of California in 2010.
Postes actifs de Peretz Partensky
| Sociétés | Poste | Début |
|---|---|---|
Pioneer Fund/NY/
 Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01/09/2017 |
ImmuneBridge, Inc.
 ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Directeur Général | 01/01/2018 |
Lemnos Labs, Inc.
 Lemnos Labs, Inc. Investment ManagersFinance Lemnos Labs Inc (Lemnos Labs) is a venture capital firm founded in 2011 by Jeremy Conrad and Helen Zelman Boniske. The firm is headquartered in San Francisco, California. | Analyste en capital-investissement | - |
Anciens postes connus de Peretz Partensky
| Sociétés | Poste | Fin |
|---|---|---|
Sourcery Technologies, Inc.
 Sourcery Technologies, Inc. Packaged SoftwareTechnology Services Sourcery Technologies, Inc. develops a payments and commerce platform that focuses on the wholesale foodservice industry. Its features include invoice storage, analytics, online bill pay and high touch services. The company was founded by Na’ama Moran and Peretz Partensky in July 2012 and is headquartered in San Francisco, CA. | Fondateur | - |
Formation de Peretz Partensky
| University of Cambridge | Graduate Degree |
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Lemnos Labs, Inc.
Lemnos Labs, Inc. Investment ManagersFinance Lemnos Labs Inc (Lemnos Labs) is a venture capital firm founded in 2011 by Jeremy Conrad and Helen Zelman Boniske. The firm is headquartered in San Francisco, California. | Finance |
Sourcery Technologies, Inc.
Sourcery Technologies, Inc. Packaged SoftwareTechnology Services Sourcery Technologies, Inc. develops a payments and commerce platform that focuses on the wholesale foodservice industry. Its features include invoice storage, analytics, online bill pay and high touch services. The company was founded by Na’ama Moran and Peretz Partensky in July 2012 and is headquartered in San Francisco, CA. | Technology Services |
Pioneer Fund/NY/
Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Finance |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Health Technology |
